Most breast cancers utilize the female hormone estrogen to grow, so drug-induced estrogen deprivation is used as a treatment in many patients. However, cancer will recur in one-third of these patients. A research team at Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center, led by Todd W. Miller, Ph.D., is trying to understand why dormant breast cancer cells survive despite being starved of estrogen. The team discovered that an anti-diabetes drug, metformin, which is being tested in many clinical trials as an anti-cancer agent, actually activated fat metabolism that protected dormant breast cancer cells during estrogen deprivation. The findings suggest that the drug has context-dependent effects on cancer cells.
The results, entitled “AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells,” are newly published online in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Metformin activates AMPK, which is a metabolic sensor that signals cells to make energy. Miller’s team found that breast cancer cells survived estrogen deprivation through activation of AMPK. “A major output of AMPK is activation of fat breakdown to produce energy, which we observed in dormant cancer cells,” says Miller. “Drugs that block fat breakdown are used to treat patients with angina (chest pain). Treatment of mice with anti-angina drugs decreased dormant cancer cell numbers.”
Knowledge that metformin has context-dependent effects on cancer cells will inform a better understanding of ongoing and prior clinical trials testing metformin, and help shape the design of trials moving forward. “Our study indicates that the development of drugs targeting fat metabolism is warranted for breast cancer. Most excitingly, anti-angina drugs that block fat metabolism may be quickly repurposed as potential treatments for cancer and tested in clinical trials,” says Miller.
Source: Read Full Article